Candida auris Candidemia: SOFA Score Predicts Mortality as Echinocandins Remain Effective First-Line Therapy
核心洞察
A two-center Saudi Arabian retrospective study of 228 C. auris candidemia patients found a 40.1% mortality rate, with higher SOFA scores independently predicting increased mortality risk (adjusted HR = 1.175, 95% CI: 1.091–1.265, p < 0.001).
Echinocandins (搜索) retained potent activity against C. auris, with anidulafungin and micafungin showing >90% susceptibility, while fluconazole resistance reached 77.1% (MIC ≥64 µg/mL).
Monotherapy was associated with faster bloodstream clearance (median 4 vs 5 days, p = 0.031) and lower recurrence rates (11.1% vs 23.7%, p = 0.021) compared to combination therapy.
A two-center retrospective cohort study from Riyadh, Saudi Arabia, has provided critical real-world data on the clinical characteristics, antifungal treatment patterns, and outcomes of Candida auris (搜索) candidemia, reinforcing the role of SOFA score as a robust mortality predictor while confirming echinocandins (搜索) as effective first-line therapy against this multidrug-resistant pathogen.
The study, which analyzed 228 adult patients with laboratory-confirmed C. auris candidemia between January 2021 and June 2024, found that 40.1% of patients died during follow-up. Higher Sequential Organ Failure Assessment (SOFA) scores emerged as an independent predictor of mortality in multivariable Cox regression analysis, with each one-point increase associated with a 17.5% increase in mortality hazard (adjusted HR = 1.175, 95% CI: 1.091–1.265, p < 0.001).
Patient Demographics and Risk Factors
The cohort had a mean age of 61.9 ± 17.8 years, with 36.0% aged 70 years and above. Gender distribution was nearly equal (51.4% males, 48.6% females). The most common comorbidities included hypertension (59.2%), diabetes mellitus requiring medication (50.0%), and moderate to severe chronic kidney disease (29.8%).
Notably, 68.6% of patients required ICU admission, and 68.0% had received broad-spectrum antibiotics within three months preceding candidemia. Prior exposure to echinocandins (搜索) was documented in 17.1% of patients, while 39.9% had received corticosteroids. These findings underscore the role of disrupted microbiota and immunosuppression in predisposing patients to invasive C. auris infection.
Antifungal Susceptibility Patterns
Antifungal susceptibility testing revealed concerning resistance patterns. Fluconazole exhibited high-level resistance, with 77.1% of isolates demonstrating MICs ≥64 µg/mL. Over 50% of isolates also showed reduced susceptibility to itraconazole, posaconazole, and voriconazole.
In contrast, echinocandins (搜索) retained potent in vitro activity. Anidulafungin showed MICs ≤1 µg/mL in 90.9% of isolates, while micafungin demonstrated similar susceptibility in 92.8% of isolates. Amphotericin B maintained susceptibility in 73.3% of isolates at MICs ≤1 µg/mL.
Treatment Strategies and Outcomes
The majority of patients (70.5%) received monotherapy throughout their treatment course, while 29.5% required combination therapy, primarily echinocandins (搜索) combined with liposomal amphotericin B. Anidulafungin (53.4%) and caspofungin (43.8%) were the most commonly used agents.
Patients treated with monotherapy experienced significantly faster bloodstream clearance compared to those on combination therapy (median 4 days, IQR = 3–5 vs median 5 days, IQR = 3.75–8; p = 0.031). Monotherapy was also associated with a lower recurrence rate of candidemia (11.1% vs 23.7%, p = 0.021).
Bacterial co-infection, observed in 22.5% of patients, was associated with delayed bloodstream clearance (p = 0.013), though it had no statistically significant impact on survival time or recurrence.
SOFA Score as Prognostic Tool
Kaplan–Meier survival analysis demonstrated progressively reduced survival probabilities across increasing SOFA severity categories. Patients in the very high-risk group (SOFA >12) demonstrated the shortest survival times. Pairwise comparisons revealed statistically significant differences in survival between the low-risk and very high-risk groups (p = 0.015), as well as between the moderate-risk and very high-risk groups (p = 0.034).
Recurrent candidemia occurred in 14.6% of patients, with C. auris identified as the causative organism in 96.4% of those cases. However, multivariable logistic regression did not identify independent predictors of recurrence, and the model demonstrated limited explanatory power (Nagelkerke R² = 0.054).
Global Context: C. auris Emergence in China
A separate 10-year retrospective study conducted at a 4,500-bed tertiary-care hospital in Eastern China, analyzing 387 candidemia patients from 2015 to 2024, reported the first isolation of C. auris at that institution in 2024. Although C. auris accounted for only 0.26% of candidemia episodes, the finding signals the pathogen's expanding geographic reach.
The Chinese study documented an overall candidemia mortality rate of 33.85%, which rose sharply to 53% in 2024. Independent risk factors for in-hospital mortality included age ≥63 years (HR = 1.530, 95% CI: 1.077–2.174, p = 0.018), ICU admission history (HR = 2.005, 95% CI: 1.200–3.350, p = 0.008), and acute or chronic renal failure (HR = 1.849, 95% CI: 1.261–2.711, p = 0.002).
The Chinese cohort also revealed high azole resistance in C. tropicalis, with 69.44% of isolates showing non-wild-type MICs to posaconazole and 27.78% exhibiting cross-resistance to fluconazole and voriconazole. Echinocandins (搜索) maintained susceptibility rates above 98.5% across the four major Candida species.
Implications for Clinical Practice
The Saudi Arabian study authors emphasized that "echinocandins (搜索), especially anidulafungin and caspofungin, remained the most effective agents, with >90% susceptibility, supporting their recommendation as first-line therapy." They further noted that "the SOFA score emerged as a robust predictor of mortality" and may serve as a useful prognostic tool for identifying high-risk patients.
Both studies highlight the critical importance of antimicrobial stewardship programs, early recognition, appropriate antifungal therapy, and infection prevention measures in managing C. auris candidemia. The emergence of C. auris in new geographic regions, even at low prevalence, warrants enhanced active surveillance and optimized infection control strategies to mitigate potential spread among high-risk populations, particularly critically ill patients.
The Saudi Arabian study has several limitations, including its retrospective observational design, conduct in only two tertiary care centers, and relatively small sample sizes for certain subgroup analyses. Colonization surveillance data were not consistently available, and recurrence analyses did not account for competing risks such as mortality.